Welcome to our dedicated page for Concord Medical SEC filings (Ticker: CCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Concord Medical Services Holdings Limited (NYSE: CCM) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Concord Medical files an annual report on Form 20-F, which includes audited financial statements and detailed information about its oncology-focused operations, including its hospital business, network business and related financial metrics.
Concord Medical also furnishes Form 6-K current reports that cover a range of material information. Recent 6-K filings reference interim financial results for the first half of the year, announcements about annual general meetings of shareholders, changes in directors, and developments at its subsidiary Concord Healthcare Group Co., Ltd., which is listed on the Main Board of The Stock Exchange of Hong Kong Limited. Other 6-Ks transmit press releases on topics such as proton therapy milestones, licensing approvals for proton equipment and share placing activities at the subsidiary level.
Through these filings, readers can track how Concord Medical reports on its oncology hospital and network businesses, non-GAAP measures such as adjusted EBITDA as defined in its releases, and corporate governance and capital markets events. While foreign issuers like Concord Medical typically do not file Forms 10-K or 10-Q, their Form 20-F and Form 6-K submissions serve similar roles in disclosing annual and interim information.
On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections and help explain complex financial and regulatory language. Users can quickly identify important disclosures in Concord Medical’s Form 20-F and 6-Ks, and monitor ongoing updates related to its oncology services, proton therapy initiatives and subsidiary activities without reading every page in full.
Concord Medical Services Holdings Limited reported that its subsidiary Concord Healthcare Group Co., Ltd., which is listed on the Main Board of The Stock Exchange of Hong Kong Limited, filed its annual report for the year ended December 31, 2025 on April 15, 2026.
The filing notes that Concord Healthcare’s H shares trade on the HKSE under stock code 2453.HK and that the annual report is available through the HKSE’s hkexnews website.
Concord Medical Services Holdings Ltd director and chief executive officer Yang Jianyu reported his initial ownership in a Form 3. He may be deemed the beneficial owner of 38,287,948 Class B ordinary shares held by Morgancreek Investment Holding Limited, all convertible into an equal number of Class A ordinary shares at no cost. He is also attributed 466,097 American depositary shares, each representing 30 Class A ordinary shares, indirectly held by Morgancreek.
Concord Medical Services director Cheng Zheng reported his initial beneficial ownership of the company’s equity. He is deemed to beneficially own 7,500,000 Class B ordinary shares, all held through Bluestone Holdings Limited, where he is the sole director and shareholder. These Class B shares are convertible at any time, at the holder’s option and at no cost, into an equal number of Class A ordinary shares.
Concord Medical Services Holdings Ltd director Wayne Yu filed an initial ownership report on Form 3. This filing identifies Yu as a director of the company but does not report any insider transactions or changes in share ownership.
Concord Medical Services Holdings Ltd filed an initial insider ownership report for Jiang Wei, who serves as Chief Financial Officer. This Form 3 establishes Jiang Wei as a reporting person for the company’s securities. The provided data does not show any buy, sell, or derivative transactions.
Concord Medical Services Holdings Ltd director Liu Hongzhong filed an initial ownership report on Form 3 for the company’s ordinary shares. The filing does not list any insider transactions; it simply establishes Liu’s status as a reporting director for future ownership and trading disclosures.
Concord Medical Services Holdings Ltd director Zhang Liping filed an initial ownership report on Form 3. The filing shows direct ownership of 135,000 Class A ordinary shares, each with a par value of US$0.0001. This form records existing holdings rather than a new purchase or sale.
Concord Medical Services Holdings Limited reported that Mr. Yue Yu resigned from its board of directors, effective September 29, 2025. The company states that his resignation is due to personal reasons and that it is not related to any disagreement with the company regarding its operations, policies, or practices. This indicates a board change without an underlying disclosed dispute over how the business is run.